<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02667418</url>
  </required_header>
  <id_info>
    <org_study_id>596</org_study_id>
    <secondary_id>#15-03</secondary_id>
    <nct_id>NCT02667418</nct_id>
  </id_info>
  <brief_title>Optimal Treatment for Recurrent Clostridium Difficile</brief_title>
  <acronym>OpTION</acronym>
  <official_title>CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether fidaxomicin and vancomycin followed by&#xD;
      taper and pulse vancomycin treatment are superior to standard vancomycin treatment for the&#xD;
      treatment of recurrent Clostridium difficile infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Abstract Clostridium difficile is the most common cause of healthcare-associated infectious&#xD;
      diarrhea among adults in industrialized countries. In addition to diarrhea, C. difficile&#xD;
      infection (CDI) may also result in serious complications such as shock, toxic megacolon,&#xD;
      colectomy, and death. The Centers for Disease Control and Prevention (CDC) has estimated C.&#xD;
      difficile results in 250,000 hospital infections, 14,000 deaths, and $1 billion in excess&#xD;
      costs annually. Recurrent CDI is the most challenging clinical dilemma facing clinicians who&#xD;
      treat this disease. An estimated 30% of patients who respond to initial treatment with either&#xD;
      vancomycin or metronidazole develop recurrent CDI, usually within 1-4 weeks of completing&#xD;
      treatment.&#xD;
&#xD;
      The primary objective of this study is to determine whether 1) standard fidaxomicin treatment&#xD;
      and 2) standard vancomycin treatment followed by taper and pulse vancomycin treatment are&#xD;
      superior to standard vancomycin treatment alone for sustained clinical response at day 59 for&#xD;
      all treatments, for participants with either their first or second recurrence of CDI.&#xD;
      Veterans presenting with a first or second CDI recurrence will be screened, consented and&#xD;
      randomly assigned in a double-blind manner equally to one of three treatment groups: 1) a 10&#xD;
      day course of oral vancomycin (VAN-TX), 2) a 10 day course of fidaxomicin (FID-TX) or 3) a 31&#xD;
      day course of vancomycin which includes a taper and pulse following daily treatment&#xD;
      (VAN-TP/P). Symptom resolution is defined as an improvement or resolution of diarrhea ( 3&#xD;
      unformed bowel movements over 24 hours) for 48 consecutive hours compared to the&#xD;
      participant's baseline. Recurrence is defined as having diarrhea (&gt;3 loose or semi-formed&#xD;
      stools over 24 hours for 48 consecutive hours). A sample size of 549 randomized study&#xD;
      participants is required to obtain 91% global power to detect a 16% absolute difference&#xD;
      (expected proportion of 31% in the VAN-TX group) in sustained clinical response (D- COM)&#xD;
      proportion for at least one comparison (VAN-TP/P vs. VAN-TX, FID-TX vs. VAN-TX) at the family&#xD;
      wised error rate (FWER) 0.05 level. The marginal probability (disjunctive power) of detecting&#xD;
      16% absolute difference for each comparison is 81%. The expected withdrawal rate prior to day&#xD;
      59 (prior outcome assessment) is estimated to be 10%. If both FID-TX and VAN-TP/P are found&#xD;
      to be superior to VAN-TX, then the non-inferiority of VAN-TP/P to FID-TX will be assessed.&#xD;
&#xD;
      With the assumption that sites recruit 6 participants (site average) per year for sites&#xD;
      primarily recruiting from the main hospital and nearby CBOCS, and 9 participants (site&#xD;
      average) per year for sites that could partner with independent VAMCs (Independent VAMCs LSI&#xD;
      Application will be reviewed and approved by Central IRB) that are close in distance to allow&#xD;
      a shared site coordinator (WOC appointed) at an increased funding level, the study is&#xD;
      expected to complete enrollment of 549 participants within 6 years with 90 days of follow-up.&#xD;
      This includes 2 years of pilot phase plus transitioning period from pilot phase to full&#xD;
      study, and 4 years of full study. There were 6 sites in the pilot phase and will have 24&#xD;
      units (26 sites) in full phase (including 5 pilot sites and 21 additional sites). Sites that&#xD;
      are significantly below the recruitment target for an extensive period may be considered for&#xD;
      termination. The recruitment timeline and the number of sites will be re-evaluated based on&#xD;
      the actual recruitment rate, the number of sites still recruiting, whether replacement or&#xD;
      additional sites will be added, the study time period on administrative recruitment hold due&#xD;
      to COVID-19 pandemic, and available funding resources.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2015</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine symptom resolution during treatment without any of the following: diarrhea recurrence; other non-fatal clinical events including severe abdominal pain, toxic megacolon, and colectomy; and death.</measure>
    <time_frame>Day 59 for all treatment regimens.</time_frame>
    <description>The Primary outcome will be sustained clinical response as measured at study day 59 for all treatment regimens. Sustained clinical response is a composite outcome that includes symptom resolution during treatment without any of the following (as assessed on day 59):&#xD;
Diarrhea recurrence&#xD;
Other non-fatal clinical events including severe abdominal pain, toxic megacolon (where diarrhea ceases but is not a beneficial outcome), and colectomy&#xD;
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CDI Composite outcome measure</measure>
    <time_frame>Day 59 for all treatment regimens.</time_frame>
    <description>CDI Composite Outcome Measure (CDI-COM) is sustained clinical response without recurrent CDI (defined as diarrhea plus confirmation of toxigenic C. difficile or its toxins in stool) as measured at study day 59 for all three treatment regimens. Sustained response will be defined using the same composite endpoint criteria as were used in the D-COM outcome but without recurrent CDI on or before day 59.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea Composite outcome measure</measure>
    <time_frame>Day 38 since randomization for vancomycin and fidaxomicin, day 59 since randomization for vancomycin followed by tapering and pulse dose regimen</time_frame>
    <description>Sustained clinical response in Diarrhea Composite Outcome (D-COM) at 28 days post end of therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea Composite outcome measure</measure>
    <time_frame>Day 90 since randomization</time_frame>
    <description>Sustained clinical response in Diarrhea Composite Outcome (D-COM) at 90 days post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDI Composite outcome measure</measure>
    <time_frame>Day 38 since randomization for vancomycin and fidaxomicin, day 59 since randomization for vancomycin followed by tapering and pulse dose regimen</time_frame>
    <description>Sustained clinical response in CDI Composite Outcome (CDI-COM) at 28 days post end of therapy. Sustained response in CDI-COM is defined using the same composite endpoint criteria as was used in the D-COM composite outcome (primary outcome) but with confirmation of no CDI recurrence by a negative C. difficile stool assay test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDI Composite outcome measure</measure>
    <time_frame>Day 59 since randomization</time_frame>
    <description>Sustained clinical response in CDI Composite Outcome (CDI-COM) at 59 days post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CDI Composite outcome measure</measure>
    <time_frame>Day 90 since randomization</time_frame>
    <description>Sustained clinical response in CDI Composite Outcome (CDI-COM) at 90 days post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom resolution</measure>
    <time_frame>Day 10 since randomization</time_frame>
    <description>Proportion of subjects with symptom resolution by day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom resolution</measure>
    <time_frame>Day 10 since randomization</time_frame>
    <description>Days from randomization to symptom resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom resolution</measure>
    <time_frame>Day 90 since randomization</time_frame>
    <description>Diarrhea recurrence following initial symptom resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea recurrence</measure>
    <time_frame>Day 90 since randomization</time_frame>
    <description>Diarrhea recurrence with confirmation of recurrent CDI following initial symptom resolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C.diff Health Related Quality of Life (HRQOL)</measure>
    <time_frame>Day 90 since randomization</time_frame>
    <description>Change in patient reported C.diff Health Related Quality of Life (HRQOL) from baseline (day 0) to day 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C.diff Health Related Quality of Life (HRQOL)</measure>
    <time_frame>Day 90 since randomization</time_frame>
    <description>Change in patient reported C.diff Health Related Quality of Life (HRQOL) from baseline (day 0) to day 59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained clinical response (D-COM)</measure>
    <time_frame>Day 59 since randomization</time_frame>
    <description>Sustained clinical response (D-COM) at day 59 for subgroups (infection with the BI/NAP1/027 strain (yes, no) at study enrollment; etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained clinical response (CDI-COM)</measure>
    <time_frame>Day 59 since randomization</time_frame>
    <description>Sustained clinical response (CDI-COM) at day 59 for subgroups (infection with the BI/NAP1/027 strain (yes, no) at study enrollment; etc.)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">549</enrollment>
  <condition>Clostridium</condition>
  <condition>Difficile</condition>
  <condition>Fidaxomicin</condition>
  <condition>Vancomycin</condition>
  <arm_group>
    <arm_group_label>Fidaxomicin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard 10-day fidaxomicin treatment for Clostridium difficile</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin T/P</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard 10-day vancomycin treatment followed by taper and pulse vancomycin treatment for Clostridium difficile</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard 10-day vancomycin treatment for Clostridium difficile</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fidaxomicin</intervention_name>
    <description>200 mg PO twice daily for 10 days</description>
    <arm_group_label>Fidaxomicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin with Taper/Pulse</intervention_name>
    <description>125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days</description>
    <arm_group_label>Vancomycin T/P</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>125 mg PO for times daily for 10 days</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained and signed&#xD;
&#xD;
          -  Age &gt; 18&#xD;
&#xD;
          -  If female, participant must not be pregnant or nursing&#xD;
&#xD;
               -  Negative pregnancy test required for females &lt;61 years of age or without prior&#xD;
                  hysterectomy&#xD;
&#xD;
          -  Confirmed current diagnosis of CDI, determined by having&#xD;
&#xD;
               -  &gt;3 loose or semi-formed stools for participants over 24 hours AND&#xD;
&#xD;
               -  Positive stool assay for C. difficile&#xD;
&#xD;
               -  EIA positive for toxin A/B; or&#xD;
&#xD;
               -  Cytotoxin assay; or&#xD;
&#xD;
               -  Nucleic Acid Amplification Test (NAAT, PCR or LAMP) based detection of toxigenic&#xD;
                  C. difficile&#xD;
&#xD;
          -  Current episode represents the first recurrent episode of CDI within 3 months of the&#xD;
             primary CDI episode in a patient who has not had CDI in the 3 months prior to the&#xD;
             primary episode OR a second recurrent CDI episode occurring within 3 months of the&#xD;
             first recurrent episode, as defined above&#xD;
&#xD;
               -  At least one of the previous CDI episodes must have been confirmed by a stool&#xD;
                  assay for C. difficile&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Inability to take oral capsules&#xD;
&#xD;
          -  Receipt of &gt;72 hours of antibiotics considered effective in the treatment of CDI,&#xD;
             including:&#xD;
&#xD;
               -  metronidazole&#xD;
&#xD;
               -  vancomycin&#xD;
&#xD;
               -  fidaxomicin&#xD;
&#xD;
               -  nitazoxanide&#xD;
&#xD;
               -  rifaximin&#xD;
&#xD;
          -  Prior infusion of bezlotoxumab within the previous 6 months&#xD;
&#xD;
          -  Known presence of fulminant CDI, including hypotension, severe ileus or GI obstruction&#xD;
             or incipient toxic megacolon&#xD;
&#xD;
          -  Receipt of more than a single course of oral vancomycin, fidaxomicin, or a vancomycin&#xD;
             tapering regimen since the primary episode of CDI as defined above&#xD;
&#xD;
          -  Known allergy to vancomycin or fidaxomicin&#xD;
&#xD;
          -  Acute or chronic diarrhea due to inflammatory bowel disease or other cause (e.g.,&#xD;
             presence of an ileostomy or colostomy) that would confound evaluation of response to&#xD;
             CDI treatment&#xD;
&#xD;
          -  Anticipation of need for long term systemic antibiotic treatment (beyond 7 days)&#xD;
&#xD;
          -  Patients with an active diagnosis of COVID-19 will be excluded from the study, but&#xD;
             patients who have recovered (per current CDC guidance on discontinuation of&#xD;
             transmission-based precautions) can be included in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart B. Johnson, MD BA</last_name>
    <role>Study Chair</role>
    <affiliation>Edward Hines Jr. VA Hospital, Hines, IL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dale N Gerding, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Edward Hines Jr. VA Hospital, Hines, IL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Johnson</last_name>
    <phone>(708) 202-8387</phone>
    <phone_ext>27001</phone_ext>
    <email>Michelle.Johnson5@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xue Li, PhD</last_name>
    <phone>(708) 202-4992</phone>
    <email>Xue.li@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix VA Health Care System, Phoenix, AZ</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Negin Blattman, MD</last_name>
      <phone>602-277-5551</phone>
      <phone_ext>6267</phone_ext>
      <email>negin.blattman2@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System, Tucson, AZ</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chinh Nguyen, MD</last_name>
      <phone>520-792-1450</phone>
      <phone_ext>4649</phone_ext>
      <email>chinh.nguyen@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205-5484</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Burns, MD</last_name>
      <phone>501-257-5950</phone>
      <email>matthew.burns2@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Ryan Dare, MD</last_name>
      <phone>5012575866</phone>
      <email>ryan.dare@va.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System, Loma Linda, CA</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>VA Long Beach Healthcare System, Long Beach, CA</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Padmaja Muthiah, MD</last_name>
      <phone>562-826-8000</phone>
      <email>Padmaja.Muthiah@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System, Palo Alto, CA</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System, San Diego, CA</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Mehta, MD</last_name>
      <phone>858-642-3019</phone>
      <email>srmehta@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Greater Los Angeles Healthcare System, West Los Angeles, CA</name>
      <address>
        <city>West Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Regional VA Medical Center, Aurora, CO</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Nicholson, MD</last_name>
      <phone>303-399-9020</phone>
      <phone_ext>3132</phone_ext>
      <email>lindsay.nicholson@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bay Pines VA Healthcare System, Pay Pines, FL</name>
      <address>
        <city>Bay Pines</city>
        <state>Florida</state>
        <zip>33744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Johnson, MD</last_name>
      <phone>727-398-6661</phone>
      <phone_ext>15905</phone_ext>
      <email>david.johnson6@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Florida/South Georgia Veterans Health System, Gainesville, FL</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary P Wang, MD</last_name>
      <phone>352-376-1611</phone>
      <phone_ext>6438</phone_ext>
      <email>gary.wang@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>James A. Haley Veterans' Hospital, Tampa, FL</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Atlanta VA Medical and Rehab Center, Decatur, GA</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abeer Moanna, MD</last_name>
      <phone>404-786-3420</phone>
      <email>Abeer.Moanna@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jesse Brown VA Medical Center, Chicago, IL</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stockton Mayer, MD</last_name>
      <phone>312-569-6129</phone>
      <email>Stockton.Mayer@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr. VA Hospital, Hines, IL</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141-5000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr. VA Hospital, Hines, IL</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Pacheco, MD</last_name>
      <phone>708-202-3394</phone>
      <email>Susan.Pacheco2@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rehabilitation R&amp;D Service, Baltimore, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Von Rosenvinge, MD</last_name>
      <phone>410-605-7000</phone>
      <phone_ext>5260</phone_ext>
      <email>erik.vonrosenvinge@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalpana Gupta, MD</last_name>
      <phone>857-203-5086</phone>
      <email>Kalpana.Gupta@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Ann Arbor Healthcare System, Ann Arbor, MI</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Bradley, MD</last_name>
      <phone>734-769-7100</phone>
      <phone_ext>7686</phone_ext>
      <email>sbradley@umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John D. Dingell VA Medical Center, Detroit, MI</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadi Antaki, MD</last_name>
      <email>Fadi.Antaki@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asheville VA Medical Center, Asheville, NC</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Scott Mahan, MD</last_name>
      <phone>828-298-7911</phone>
      <phone_ext>5086</phone_ext>
      <email>charles.mahan@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Durham VA Medical Center, Durham, NC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Hostler, MD</last_name>
      <email>Christopher.Hostler@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Louis Stokes VA Medical Center, Cleveland, OH</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curtis Donskey, MD</last_name>
      <phone>216-791-3800</phone>
      <phone_ext>8204788</phone_ext>
      <email>Curtis.Donskey@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oklahoma City VA Medical Center, Oklahoma City, OK</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Kurdgelashvili, MD</last_name>
      <email>George.Kurdgelashvili@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Pfeiffer, MD</last_name>
      <phone>503-220-8262</phone>
      <phone_ext>58127</phone_ext>
      <email>christopher.pfeiffer2@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Cutrell, MD</last_name>
      <phone>214-857-2290</phone>
      <email>james.cutrell@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center, Houston, TX</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward J Young, MD</last_name>
      <phone>713-794-7589</phone>
      <email>Edward.Young@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Texas Health Care System, San Antonio, TX</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Johnson, MD</last_name>
      <phone>801-582-1565</phone>
      <phone_ext>1236</phone_ext>
      <email>jessica.b.johnson@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System Seattle Division, Seattle, WA</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Clement J. Zablocki VA Medical Center, Milwaukee, WI</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295-1000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javeria Haque, MD</last_name>
      <email>Javeria.Haque@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Caribbean Healthcare System, San Juan, PR</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium</keyword>
  <keyword>Difficile</keyword>
  <keyword>Fidaxomicin</keyword>
  <keyword>Vancomycin</keyword>
  <keyword>Recurrent</keyword>
  <keyword>Pulse</keyword>
  <keyword>Taper</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Fidaxomicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

